Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell–Mediated Tumor Immunity

Abstract

Sialic acid sugars on the surface of cancer cells have emerged as potent immune modulators that contribute to the immunosuppressive microenvironment and tumor immune evasion. However, the mechanisms by which these sugars modulate antitumor immunity as well as therapeutic strategies directed against them are limited. Here we report that intratumoral injections with a sialic acid mimetic Ac3FNeu5Ac block tumor sialic acid expression and suppress tumor growth in multiple tumor models. Sialic acid blockade had a major impact on the immune cell composition of the tumor, enhancing tumor-infiltrating natural killer cell and CD8 T-cell numbers while reducing regulatory T-cell and myeloid regulatory cell numbers. Sialic acid blockade enhanced cytotoxic CD8 T-cell-mediated killing of tumor cells in part by facilitating antigen-specific T-cell-tumor cell clustering. Sialic acid blockade also synergized with adoptive transfer of tumor-specific CD8 T cells and enhanced CpG immune adjuvant therapy by increasing dendritic cell activation and subsequent CD8 T-cell responses. Collectively, these data emphasize the crucial role of sialic acids in tumor immune evasion and provide proof of concept that sialic acid blockade creates an immune-permissive tumor microenvironment for CD8 T-cell-mediated tumor immunity, either as single treatment or in combination with other immune-based intervention strategies. Sialic acid sugars function as important modulators of the immunosuppressive tumor microenvironment that limit potent antitumor immunity. http://cancerres.aacrjournals.org/content/canres/78/13/3574/F1.large.jpg .

CRISPR-based screens uncover determinants of immunotherapy response in Multiple Myeloma

“…Although our BCMAexpression screen identified these genes to upregulate BCMA, the effect size of sensitizing the cells to CAR-T cells was much higher than the change in BCMA expression, indicating that there could be additional mechanisms by which this pathway modulates response to CAR-T cells. Sialic acid blockade in cancer cells has been shown to create an immune-permissive tumor microenvironment increasing CD8+ T cell activity (39). Therefore, inhibition of GALE and/or GNE could modulate the tumor microenvironment and increase sensitivity to CAR-T cells in an antigen-independent mechanism.…”

Systematic identification of regulators of antibody-drug conjugate toxicity using CRISPR-Cas9 screens

“…Notably, 3F-NeuAc is effective in reducing global glycan sialylation in mice but has deleterious "on-target" effects such as impairing liver and kidney function 63 . This systemic toxicity can be circumvented by intratumoral injections of 3F-NeuAc, resulting in decreased tumor sialylation levels 64 . Another possible means to implement this strategy would be to utilize targeted-glycan modification, in which sialidases conjugated to antibodies are recruited to target cells to remove cell surface sialic acids 65 .…”

In situ antitumor vaccination: Targeting the tumor microenvironment

“…CpG, a TLR9 agonist, has shown potent antitumor activity. Tumor‐induced dendritic cells (DCs) paralysis could be reversed by the combination of a CpG immunostimulatory sequence and a sialic acid mimetic Ac53FaxNeu5Ac (Bull et al, 2018). Intratumoral CpG‐B promoted antitumoral neutrophil, cDC, and T‐cell cooperation, thus disrupting the tolerogenic tumor microenvironment while suppressing tumor growth (Humbert, Guery, Brighouse, Lemeille, & Hugues, 2018).…”